...
首页> 外文期刊>Pharmaceutical Nanotechnology >Polymer-Drug Nanoconjugate - An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
【24h】

Polymer-Drug Nanoconjugate - An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs

机译:聚合物-药物纳米共轭物-创新的纳米药物:有效递送难溶药物的合理配方设计的挑战和最新进展

获取原文
获取原文并翻译 | 示例

摘要

Background: Over the last four decades, the use of water soluble polymers in rational formulation design has rapidly evolved into valuable drug delivery strategies to enhance the safety and therapeutic effectiveness of poorly soluble drugs, particularly anticancer drugs. Novel advances in polymer chemistry have provided new generations of well defined polymeric architectures for specific applications in polymer-drug conjugate design. However, total control of crucial parameters such as particle size, molecular weight distribution, polydispersity, localization of charges, hydrophilic-lipophilic balance and non site-specific coupling reactions during conjugation has been a serious challenge. Objective: This review briefly describes the current advances in polymer-drug nanoconjugate design and various challenges hindering their transformation into clinically useful medicines. Method: Existing literature was reviewed. Results: This review provides insights into the significant impact of covalent and non-covalent interactions between drug and polymer on drug loading [or conjugation] efficiency, conjugate stability, mechanism of drug release from the conjugate and biopharmaceutical properties of poorly soluble drugs. The utility values and application of Quality by Design principles in rational design, optimization and control of the Critical Quality Attributes [CQA] and Critical Process Parameters [CPP] that underpin the safety, quality and efficacy of the nanoconjugates are also presented. Conclusion: It was apparent that better understanding of the physicochemical properties of the nanoconjugates as well as the drug-polymer interaction during conjugation process is essential to be able to control the biodistribution, pharmacokinetics, therapeutic activity and toxicity of the nanoconjugates which will in turn enhance the prospect of successful transformation of these promising nanoconjugates into clinically useful nanomedicines.
机译:背景:在过去的四十年中,在合理的配方设计中使用水溶性聚合物已迅速发展成为有价值的药物递送策略,以提高难溶性药物(尤其是抗癌药物)的安全性和治疗效果。聚合物化学领域的新进展为聚合物-药物缀合物设计中的特定应用提供了新一代定义明确的聚合物体系结构。然而,在结合过程中对关键参数(如粒径,分子量分布,多分散性,电荷定位,亲水亲脂平衡和非位点特异性偶联反应)的总体控制一直是一个严峻的挑战。目的:本文简要介绍了聚合物-药物纳米共轭物设计的最新进展以及阻碍其转变为临床有用药物的各种挑战。方法:回顾现有文献。结果:本综述提供了关于药物与聚合物之间共价和非共价相互作用对药物装载[或结合]效率,结合物稳定性,从结合物释放药物的机制以及难溶性药物的生物药学特性的重大影响的见解。还提出了“合理设计”原则在合理设计,优化和控制关键质量属性[CQA]和关键工艺参数[CPP]中的实用价值和应用,这些关键属性是纳米复合物的安全性,质量和功效的基础。结论:显然,更好地了解纳米缀合物的理化性质以及缀合过程中的药物-聚合物相互作用对于控制纳米缀合物的生物分布,药代动力学,治疗活性和毒性至关重要,而这反过来会增强这些有希望的纳米共轭物成功转化为临床有用的纳米药物的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号